Rhenovia Pharma SAS

RHENOVIA Pharma is a French biotech company founded in 2007 by an international team comprising executives of the big pharmaceutical industry and world experts in the fields of neurosciences and modeling of the nervous system. In less than 5 years, Rhenovia became a biosimulation world leader in CNS. Its worldwide unique modeling technology makes it possible to reproduce on computers the cellular and molecular mechanisms of the brain and the neuronal transmission. Rhenovia uses its technology to create computational models that simulate the condition of healthy persons or affected by pathologies of the nervous system (Alzheimer, Parkinson, epilepsy, schizophrenia, depression). These simulators make it possible to predict the effectiveness and toxicity of molecules and combinations of molecules. The relevance of Rhenovia's breakthrough biosimulation technology was shown not only by comparing its results with experimental data obtained from independent laboratories, but also through the discovery of new drug candidates (Huntington's disease) and the identification of toxicity or side-effects of molecules under development. Rhenovia's studies for the pharma and biotech industry consist of service offers or research and development partnerships to decrease new drugs development timelines while reducing risks and associated costs. Rhenovia's technology also finds applications in the agro-food industry and is also applicable to neurotoxicity for civil and military applications.